Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias

Laura Hinze, Sabine Schreek, Andre Zeug, PhD, Evgeni Ponimaskin, PhD, Roxane Labrosse, MD FRCPC, James Degar, Gabriela Chiosis, PhD, Sung-Yun Pai, MD, Kristen E. Stevenson, MS, Donna S Neuberg, ScD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Martin Stanulla, MD, Alejandro Gutierrez, MD

Blood (2019) 134 (Supplement_1): 169.

https://doi.org/10.1182/blood-2019-126633

Published: 2019

Journal Articles

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Eloisi Caldas Lopes, PhD, Tai Wang, PhD, David S Jayabalan, MSc, Tony Taldone, PhD, Jorge Monge, MD, Jorge Contreras, MD, Yip Winnie, Vicenta Trujillo, PhD, Panchal Palak, Nicholas Lombardi, Sharma Sahil, PhD, Digwal Chander, PhD, Morton Coleman, MD, Gabriela Chiosis, PhD, Ruben Niesvizky, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 4399.

https://doi.org/10.1182/blood-2019-125267

Published: 2019

Journal Articles

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Justin D. Kaner, MD, Montreh Tavakkoli, MA,MD, Lisa Toudic, Brett M. Stevens, PhD, Craig T Jordan, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Ellen K. Ritchie, MD, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Sangmin Lee, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 3935.

https://doi.org/10.1182/blood-2019-128276

Published: 2019

Journal Articles

Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, Puh-71, in Acute Myeloid Leukemia

Montreh Tavakkoli, MA,MD, Justin D. Kaner, MD, Sharma Sahil, PhD, Tony Taldone, PhD, Swathi Merugu, PhD, Gabriela Chiosis, PhD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 5145.

https://doi.org/10.1182/blood-2019-125175

Published: 2019

Journal Articles

Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1435.

https://doi.org/10.1182/blood-2018-99-118764

Published: 2018

Journal Articles

HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas

Maria Nieves Calvo Vidal, PhD, Jan Krumsiek, PhD, Jayeshkumar Patel, MS, Shao Ning Yang, Jude M Phillip, DPhil, Rossella Marullo, MD PhD, Tony Taldone, PhD, Giorgio Inghirami, MD, Ari Melnick, MD, Gabriela Chiosis, PhD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 645.

https://doi.org/10.1182/blood.V130.Suppl_1.645.645

Published: 2017

Journal Articles

HSP90 Stabilizes B-Cell Receptor Kinases in a Multi-Client Interactome: PU-H71 Induces CLL Apoptosis in a Cytoprotective Microenvironment

Yue Lynn Wang, MD PhD, Pin Lu, PhD, Jimmy Lee, MD, Chao Jie Zhen, BS, Gabriela Chiosis, PhD, Ailin Guo, Ph DMD

Blood (2016) 128 (22): 5105.

https://doi.org/10.1182/blood.V128.22.5105.5105

Published: 2016

Journal Articles

A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML

Hongliang Zong, MD PhD, Tony Taldone, PhD, Gail J. Roboz, MD, Gabriela Chiosis, PhD, Monica L. Guzman, PhD

Blood (2015) 126 (23): 2567.

https://doi.org/10.1182/blood.V126.23.2567.2567

Published: 2015

Journal Articles

Targeting the Hsp90 Oncoproteome in Burkitt Lymphoma

Lisa Giulino Roth, MD, Herman van Besien, Anna Rodina, PhD, Tony Taldone, PhD, Hediye Erdjument-Bromage, PhD, Matthew J. Barth, MD, Gabriela Chiosis, PhD, Ethel Cesarman

Blood (2015) 126 (23): 592.

https://doi.org/10.1182/blood.V126.23.592.592

Published: 2015

Journal Articles

An HSP90 Inhibitor, PU-H71, Antagonizes Stroma-Induced Pro-Survival Effects in CLL through Its Inhibition of Multi-Component B-Cell Receptor Signaling Pathway

Ailin Guo, PhDMD, Pin Lu, PhD, Chaojie Zhen, PhD, Gabriela Chiosis, PhD, Yue Lynn Wang, MD PhD

Blood (2015) 126 (23): 5289.

https://doi.org/10.1182/blood.V126.23.5289.5289

Published: 2015

Journal Articles

Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells

Nieves Calvo-Vidal, PhD, Jayeshkumar Patel, MS, Jan Krumsiek, PhD, Thibault Dupont, Rebecca Goldstein, BA, Shao Ning Yang, MS, Ari Melnick, MD, Gabriela Chiosis, PhD, Leandro Cerchietti, MD

Blood (2014) 124 (21): 1764.

https://doi.org/10.1182/blood.V124.21.1764.1764

Published: 2014

Journal Articles

BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain

Tharu M Fernando, MS, Shao Ning Yang, MS, Chuanxin Huang, PhD, Gabriela Chiosis, PhD, Leandro Cerchietti, MD, Ari M. Melnick, MD

Blood (2014) 124 (21): 567.

https://doi.org/10.1182/blood.V124.21.567.567

Published: 2014

Journal Articles

HSP70 Inhibitor, YK5, Synergizes with Chemotherapeutic Agents and Prevents Chemoresistance in Acute Myelogenous Leukemia (AML).

Krishan K. Sharma, Juan Felipe Rico, MD, Michael W. Becker, MD, Gail J. Roboz, MD, Gabriela Chiosis, PhD, Monica L. Guzman, PhD

Blood (2012) 120 (21): 2476.

https://doi.org/10.1182/blood.V120.21.2476.2476

Published: 2012

Journal Articles

Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo

Ross L. Levine, Priya Koppikar, Sachie Marubayashi, Neha Bhagwat, Tony Taldone, PhD, Christopher Y. Park, MD, PhD, Gabriela Chiosis, PhD

Blood (2012) 120 (21): 805.

https://doi.org/10.1182/blood.V120.21.805.805

Published: 2012

Journal Articles

Anti-Apoptotic Bcl2 and Bcl-Xl Proteins Involved in Stroma-Induced Drug Tolerance to Hsp70 and Hsp90 Inhibitors in Leukemia and B-Cell Lymphoma

Eloisi Caldas Lopes, Fabian M Correa, Ling-Bo Shen, Jae-Hung Shieh, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Malcolm A.S. Moore, PhD

Blood (2012) 120 (21): 4900.

https://doi.org/10.1182/blood.V120.21.4900.4900

Published: 2012

Journal Articles

HSP70 Inhibitor, YK5, Ablates Blast, Progenitor and Stem Cell Populations in Primary Acute Myelogenous Leukemia Cells

Juan Felipe Rico, MD, Krishan K. Sharma, Yanlong Kang, PhD, Tony Taldone, PhD, Hardik Patel, Sarah Brennan, PhD, Hongliang Zong, MD, PhD, Michael W. Becker, MD, Gail J. Roboz, MD, Gabriela Chiosis, PhD, Monica L. Guzman, PhD

Blood (2011) 118 (21): 2493.

https://doi.org/10.1182/blood.V118.21.2493.2493

Published: 2011

Journal Articles

FLT3-ITD+ AML Blast, Progenitor and Stem Cell Populations Demonstrate Higher Sensitivity to the Hsp90 Inhibitor PU-H71,

Hongliang Zong, MD, PhD, Tony Taldone, PhD, James H. Ahn, Sarah Brennan, PhD, Jeanne P. De Leon, Michael W. Becker, MD, Gail J. Roboz, MD, Gabriela Chiosis, PhD, Monica L. Guzman, PhD

Blood (2011) 118 (21): 3500.

https://doi.org/10.1182/blood.V118.21.3500.3500

Published: 2011

Journal Articles

Dysregulated Expression of HSP70 Isoforms in Acute Myelogenous Leukemia (AML)

Krishan K. Sharma, Juan Felipe Rico, MD, Duane C Hassane, PhD, Gabriela Chiosis, PhD, Monica L. Guzman, PhD

Blood (2011) 118 (21): 1370.

https://doi.org/10.1182/blood.V118.21.1370.1370

Published: 2011

Journal Articles

Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

Neha Bhagwat, Priya Koppikar, Outi Kilpivaara, Taghi Manshouri, PhD, Mazhar Adli, Ann Mullally, MD, Omar Abdel-Wahab, MD, Laura Leung, Abby Weinstein, Sachie Marubayashi, Aviva Goel, Mithat Gonen, Zeev Estrov, Benjamin L. Ebert, MD, D.Phil, Gabriela Chiosis, PhD, Bradley Bernstein, Srdan Verstovsek, MD, PhD, Ross L Levine, MD

Blood (2011) 118 (21): 122.

https://doi.org/10.1182/blood.V118.21.122.122

Published: 2011

Journal Articles

Synergy of the Purine-Scaffold HSP90 Inhibitor, PU-H71, with Doxorubicin in Non-Hodgkin’s Lymphoma Cell Lines.

Lyuba Varticovski, MD, Mollie H. Wright, Eloisi Caldas-Lopes, PhD, Gabriela Chiosis, PhD, Ana I. Robles, PhD

Blood (2007) 110 (11): 1399.

https://doi.org/10.1182/blood.V110.11.1399.1399

Published: 2007

NARROW

Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, Puh-71, in Acute Myeloid Leukemia

Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia

HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas

HSP90 Stabilizes B-Cell Receptor Kinases in a Multi-Client Interactome: PU-H71 Induces CLL Apoptosis in a Cytoprotective Microenvironment

A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML

Targeting the Hsp90 Oncoproteome in Burkitt Lymphoma

An HSP90 Inhibitor, PU-H71, Antagonizes Stroma-Induced Pro-Survival Effects in CLL through Its Inhibition of Multi-Component B-Cell Receptor Signaling Pathway

Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells

BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain

HSP70 Inhibitor, YK5, Synergizes with Chemotherapeutic Agents and Prevents Chemoresistance in Acute Myelogenous Leukemia (AML).

Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo

Anti-Apoptotic Bcl2 and Bcl-Xl Proteins Involved in Stroma-Induced Drug Tolerance to Hsp70 and Hsp90 Inhibitors in Leukemia and B-Cell Lymphoma

HSP70 Inhibitor, YK5, Ablates Blast, Progenitor and Stem Cell Populations in Primary Acute Myelogenous Leukemia Cells

FLT3-ITD+ AML Blast, Progenitor and Stem Cell Populations Demonstrate Higher Sensitivity to the Hsp90 Inhibitor PU-H71,

Dysregulated Expression of HSP70 Isoforms in Acute Myelogenous Leukemia (AML)

Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

Synergy of the Purine-Scaffold HSP90 Inhibitor, PU-H71, with Doxorubicin in Non-Hodgkin’s Lymphoma Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only